Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma

Richard Foster, John P. Donohue

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Purpose: We review the rationale for the use of retroperitoneal lymph node dissection for clinical stage I nonseminomatous testis cancer. Materials and Methods: The published literature regarding the alternative treatments for clinical stage I nonseminoma was reviewed as well as the personal experience of the authors to define the role of retroperitoneal lymph node dissection. Results: Retroperitoneal lymph node dissection alone is curative in 50% to 75% of patients with pathological stage II disease. The only significant long-term morbidity is a 1% chance of small bowel obstruction. If recurrence develops after retroperitoneal lymph node dissection, it is virtually always curable with cisplatin based chemotherapy. Conclusions: Retroperitoneal lymph node dissection retains a therapeutic and staging capability in these patients. The probability for cure, short and long-term morbidity, and minimal need for long-term followup in these patients indicates that retroperitoneal lymph node dissection continues to be standard therapy for clinical stage I nonseminoma.

Original languageEnglish
Pages (from-to)1788-1792
Number of pages5
JournalJournal of Urology
Volume163
Issue number6
StatePublished - Jun 2000

Fingerprint

Lymph Node Excision
Morbidity
Testicular Neoplasms
Cisplatin
Therapeutics
Recurrence
Drug Therapy

Keywords

  • Lymph node excision
  • Neoplasm metastasis
  • Testicular neoplasms
  • Testis

ASJC Scopus subject areas

  • Urology

Cite this

Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma. / Foster, Richard; Donohue, John P.

In: Journal of Urology, Vol. 163, No. 6, 06.2000, p. 1788-1792.

Research output: Contribution to journalArticle

@article{d2cebcf4d9da4d5f874433aaad3a390d,
title = "Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma",
abstract = "Purpose: We review the rationale for the use of retroperitoneal lymph node dissection for clinical stage I nonseminomatous testis cancer. Materials and Methods: The published literature regarding the alternative treatments for clinical stage I nonseminoma was reviewed as well as the personal experience of the authors to define the role of retroperitoneal lymph node dissection. Results: Retroperitoneal lymph node dissection alone is curative in 50{\%} to 75{\%} of patients with pathological stage II disease. The only significant long-term morbidity is a 1{\%} chance of small bowel obstruction. If recurrence develops after retroperitoneal lymph node dissection, it is virtually always curable with cisplatin based chemotherapy. Conclusions: Retroperitoneal lymph node dissection retains a therapeutic and staging capability in these patients. The probability for cure, short and long-term morbidity, and minimal need for long-term followup in these patients indicates that retroperitoneal lymph node dissection continues to be standard therapy for clinical stage I nonseminoma.",
keywords = "Lymph node excision, Neoplasm metastasis, Testicular neoplasms, Testis",
author = "Richard Foster and Donohue, {John P.}",
year = "2000",
month = "6",
language = "English",
volume = "163",
pages = "1788--1792",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma

AU - Foster, Richard

AU - Donohue, John P.

PY - 2000/6

Y1 - 2000/6

N2 - Purpose: We review the rationale for the use of retroperitoneal lymph node dissection for clinical stage I nonseminomatous testis cancer. Materials and Methods: The published literature regarding the alternative treatments for clinical stage I nonseminoma was reviewed as well as the personal experience of the authors to define the role of retroperitoneal lymph node dissection. Results: Retroperitoneal lymph node dissection alone is curative in 50% to 75% of patients with pathological stage II disease. The only significant long-term morbidity is a 1% chance of small bowel obstruction. If recurrence develops after retroperitoneal lymph node dissection, it is virtually always curable with cisplatin based chemotherapy. Conclusions: Retroperitoneal lymph node dissection retains a therapeutic and staging capability in these patients. The probability for cure, short and long-term morbidity, and minimal need for long-term followup in these patients indicates that retroperitoneal lymph node dissection continues to be standard therapy for clinical stage I nonseminoma.

AB - Purpose: We review the rationale for the use of retroperitoneal lymph node dissection for clinical stage I nonseminomatous testis cancer. Materials and Methods: The published literature regarding the alternative treatments for clinical stage I nonseminoma was reviewed as well as the personal experience of the authors to define the role of retroperitoneal lymph node dissection. Results: Retroperitoneal lymph node dissection alone is curative in 50% to 75% of patients with pathological stage II disease. The only significant long-term morbidity is a 1% chance of small bowel obstruction. If recurrence develops after retroperitoneal lymph node dissection, it is virtually always curable with cisplatin based chemotherapy. Conclusions: Retroperitoneal lymph node dissection retains a therapeutic and staging capability in these patients. The probability for cure, short and long-term morbidity, and minimal need for long-term followup in these patients indicates that retroperitoneal lymph node dissection continues to be standard therapy for clinical stage I nonseminoma.

KW - Lymph node excision

KW - Neoplasm metastasis

KW - Testicular neoplasms

KW - Testis

UR - http://www.scopus.com/inward/record.url?scp=0034081403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034081403&partnerID=8YFLogxK

M3 - Article

VL - 163

SP - 1788

EP - 1792

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -